This paper describes the function and contribution of family-oriented oncologic rehabilitation (FOR) and of oncologic rehabilitation for adolescents and young adults (AYA). The rehabilitation of children with cancer and their families and that of AYA is an integral component of pediatric oncologic treatment regimens. 32 years ago, FOR was developed in Germany and continues in a select number of highly-specialized rehabilitation centers recommended by the GPOH (Gesellschaft für Pädiatrische Onkologie und Hämatologie, Society of Pediatric Oncology and Hematology). After oncologic treatment, the patient, along with his or her family, begins an individualized rehabilitation process. The whole family participates in this process to ensure success. AYA patients are rehabilitated in small peer groups. In FOR, the immediate goal is to stabilize the family system in order to ensure maximum success for the patient. The long-term goal of FOR and AYA rehabilitation is to provide support for a return to as normal and self-determined a life as possible. Patients who suffer from chronic illnesses due to their oncologic disease and therapy (for example, a significant number of brain tumor patients) need long-term help in various areas. Here, multiple 4-week cycles of oncologic rehabilitation may be necessary throughout a patient's lifetime.

Journal Section:
Review Article
Keywords:
Pediatric oncology, Family-oriented rehabilitation, AYA
1.
Positionspapier zur familienorientierten Rehabilitation bei krebskranken Kindern; www.kinderkrebsinfo.de/sites/kinderkrebsinfo/content/e1676/e176475/e176625/e176633/POSITP∼2_ger.pdf.
2.
Verfahrensabsprache zu Anträgen der Familienorientierten Rehabilitation; www.aok-gesundheitspartner.de/imperia/md/gpp/bund/reha/leistungen/mutter_vater_kind/reha_verfahrensabsprache_familienorientierte_reha_01102009.pdf.
3.
Inhestern L, Beierlein V, Krauth KA, Schulte T, Berger D, Koch U, Bergelt C: Burden and rehabilitation goals of families in pediatric-oncological rehabilitation. Prax Kinderpsychol Kinderpsychiat 2017;66:194-208.
4.
Inhestern L, Beierlein V, Krauth KA, Rolfes U, Schulte T, Berger D, Koch U, Bergelt C: Burden of parents of pediatric cancer patients in pediatric oncological rehabilitation. Prax Kinderpsychol Kinderpsychiat 2017:66;179-193.
5.
Geue K, Mehner A, Leuteritz K: Psychosocial life situation and psycho-oncological care of young adults with cancer (AYA). Forum 2016;31:311-314.
6.
REPOH - Rehabilitation in der pädiatrischen Onkologie und Hämatologie; www.gpoh.de/fachgremien-arbeitsfelder/arbeitsgemeinschaften/repoh/.
7.
Däggelmann J, Krauth KA, Mailand P, Nopper S, Renniger M, Bündegen L, Rustler V, Bloch W, Baumann FT: Einfluss einer vierwöchigen familienorientierten Rehabilitation auf die motorische Leistungsfähigkeit, Lebensqualität und Fatigue bei krebskranken Kindern und gesunden Geschwistern. Rehabilitation 2017;56:119-126.
8.
Müller C, Rosenbaum D, Krauth KA: Prospective Evaluation of postural control and gait in pediatric patients with cancer after a 4-week inpatient rehabilitation program. Am J Phys Med Rehabil 2017;96:646-653.
9.
Müller C, Krauth KA, Gerß J, Rosenbaum D: Physical activity and health-related quality of life in pediatric patients following a 4-week inpatient rehabilitation program. Support Care Cancer 2016;24:3793-3802.
10.
Peikert ML, Inhestern L, Bergelt C: The role of rehabilitation measures in reintegration of children with brain tumors or leukemia and their families after completion of cancer treatment: a study protocol. BMJ Open 2017;7:e014505.
© 2017 S. Karger GmbH, Freiburg
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2017
You do not currently have access to this content.